Victory Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$829K Sell
37,928
-403
-1% -$8.38K ﹤0.01% 1958
2026
Q1
$895K Buy
38,331
+28,624
+295% +$622K ﹤0.01% 1884
2025
Q4
$204K Buy
+9,707
New +$169K ﹤0.01% 2202
2025
Q2
Sell
-10,148
Closed -$125K 2551
2025
Q1
$125K Buy
10,148
+119
+1% +$1.68K ﹤0.01% 2284
2024
Q4
$133K Sell
10,029
-56
-0.6% -$958 ﹤0.01% 2302
2024
Q3
$194K Sell
10,085
-255
-2% -$5.27K ﹤0.01% 2232
2024
Q2
$212K Sell
10,340
-265
-2% -$5.55K ﹤0.01% 2188
2024
Q1
$252K Buy
+10,605
New +$237K ﹤0.01% 2159
2023
Q2
Sell
-16,033
Closed -$339K 2594
2023
Q1
$339K Sell
16,033
-5,871
-27% -$146K ﹤0.01% 2113
2022
Q4
$557K Sell
21,904
-6,160
-22% -$144K ﹤0.01% 1976
2022
Q3
$675K Buy
28,064
+6,656
+31% +$149K ﹤0.01% 1912
2022
Q2
$412K Buy
21,408
+1,582
+8% +$26.4K ﹤0.01% 2136
2022
Q1
$332K Buy
+19,826
New +$334K ﹤0.01% 2262
2020
Q2
Sell
-4,286
Closed -$47K 3183
2020
Q1
$47K Buy
+4,286
New +$40.2K ﹤0.01% 2541
2019
Q4
Sell
-4,440
Closed -$33K 3195
2019
Q3
$33K Buy
+4,440
New +$40.4K ﹤0.01% 2867

Other funds holding SNDX

Victory Capital Management's SNDX Position: Q2 2026 in Review

Victory Capital Management reduced its Syndax Pharmaceuticals (SNDX) stake by 1.1% in Q2 2026, selling an estimated $8.38K and leaving 37,928 shares worth $829K. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Victory Capital Management first reported a position in SNDX in Q3 2019 and has held it in 15 quarters since. The position peaked at $895K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Victory Capital Management held 37,928 shares of Syndax Pharmaceuticals worth $829K as of Q2 2026.
  • Victory Capital Management sold 403 Syndax Pharmaceuticals shares in Q2 2026, an estimated $8.38K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1958 holding.
  • Victory Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2019 and has held it in 15 quarters since.
  • Victory Capital Management's Syndax Pharmaceuticals position peaked at $895K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.